PITTSTON, ME — (Marketwire) — 03/04/13 — YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) is pleased to announce the Integrative Stem Cell Institute (ISCI) has released three proprietary documents for patients seeking stem cell based therapies. These documents concerning stem cell procedures will be available to both new and existing patients.
The three articles that the ISCI has published are:
The ISCI Vetting Stem Cell Clinics provides a clear and concise overview of areas patients need to investigate prior to seeking stem cell therapy. The article provides information on how to evaluate claims made by the clinic, the importance of independent review of the treatments, as well as an explanation about the importance of long-term follow up.
20 Questions to Ask a Physician provides critical questions patients should ask before seeking treatment. Patients are urged to read the article, which discusses how cells are removed and injected into the patients, as well as how to determine the qualification of the physicians.
Patient Rights details patient rights and includes a thorough discussion on how patients should be treated by clinics and physicians. It also sets expectations of treatment while defining the level of care and service to be afforded to all patients. The ISCI believes patients should understand their role in a clinical study and understand there can be no guarantees.
“The ISCI has set the bar extremely high,” said David Audley, CEO of the ISCI. “No other clinic has taken such a bold, public stance on patient care and safety. These documents are a powerful collection of questions and observations that range from collection and processing of cells, to outcome tracking and access to access to medical records. These are the most complete and comprehensive set of views to protect and educate patients. We believe we have set the standard for every clinic, while enshrining transparency and protecting patient safety.”
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.
Contact:
The Integrative Stem Cell Institute
Contact: Miranda Abrahams
Investor Contact
Atlanta Capital Partners, LLC
David Kugelman
(866) 692-6847
You must be logged in to post a comment Login